Journal of Immunology Research

Peptide-Based Immunotherapeutics and Vaccines


Publishing date
29 Nov 2013
Status
Published
Submission deadline
12 Jul 2013

Lead Editor

1Department of Microbiology, Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain

2Inmunotek S.L., Alcalá de Henares, 28805 Madrid, Spain

3Medicines Research Unit, Aston University, Birmingham B4 7ET, UK

4ATR, LLC, Worcester, MA 01606, USA

5Department of Mycobacteriology, National Institute of Infectious Diseases, Higashi-Murayama, Tokyo 189-0002, Japan


Peptide-Based Immunotherapeutics and Vaccines

Description

An improved understanding of antigen presentation and recognition has enabled the development of new types of vaccines and immunotherapies based on synthetic peptides encompassing B- and T- cell epitopes. The design of such vaccines takes advantage of emergent computational and experimental technologies that facilitate the identification of epitopes within protein antigens.

Peptide-based vaccines offer several advantages over traditional vaccines. Chiefly, they allow the immune response to focus solely on relevant epitopes, avoiding those that lead to non-protective responses, immune evasion, or unwanted side effects, such as autoimmunity. However, the development of effective peptide-based vaccines requires overcoming significant difficulties, including identifying optimal delivery routes, overcoming the low immunogenicity of peptides, combining different type of epitopes to engage the humoral and cellular arms of the adaptive immune response, and compensating for the poor population coverage of individual T-cell epitopes due to MHC restriction. Moreover, certain antigenic epitopes, specifically B-cell epitopes, are conformational and need to be mimicked by linear sequences or placed onto suitable spatial frameworks.

We invite authors to submit original research and review articles addressing any of these issues in the development of peptide-based vaccines against infectious diseases, cancer, allergy, and autoimmune diseases. Potential topics include, but are not limited to:

  • New advances in epitope prediction and large-scale epitope discovery
  • Current progress in characterizing peptide repertoires presented by tumor and antigen presenting cells
  • New approaches for increasing peptide immunogenicity and optimizing the delivery of peptide-based vaccines
  • Development of peptide-based vaccines for the treatment of infectious diseases
  • Development of prophylactic and therapeutic peptide-based vaccines against cancer
  • Peptide-based immunotherapy for allergic and autoimmune diseases

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/jir/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/jir/pbiv/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2014
  • - Article ID 256784
  • - Editorial

Peptide-Based Immunotherapeutics and Vaccines

Pedro A. Reche | Enrique Fernandez-Caldas | ... | Yoshihiko Hoshino
  • Special Issue
  • - Volume 2014
  • - Article ID 764028
  • - Research Article

Immunological Responses and Epitope Mapping by Tuberculosis-Associated Antigens within the RD1 Region in Japanese Patients

Hideaki Nagai | Maho Suzukawa | ... | Yoshihiko Hoshino
  • Special Issue
  • - Volume 2014
  • - Article ID 768515
  • - Research Article

Model for Vaccine Design by Prediction of B-Epitopes of IEDB Given Perturbations in Peptide Sequence, In Vivo Process, Experimental Techniques, and Source or Host Organisms

Humberto González-Díaz | Lázaro G. Pérez-Montoto | Florencio M. Ubeira
  • Special Issue
  • - Volume 2013
  • - Article ID 263952
  • - Research Article

Prediction of IL4 Inducing Peptides

Sandeep Kumar Dhanda | Sudheer Gupta | ... | G. P. S. Raghava
  • Special Issue
  • - Volume 2013
  • - Article ID 493138
  • - Review Article

Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?

Anne S. De Groot | Leslie Cousens | ... | William Martin
  • Special Issue
  • - Volume 2013
  • - Article ID 485213
  • - Research Article

Effects of Muscarinic Acetylcholine 3 Receptor208-227 Peptide Immunization on Autoimmune Response in Nonobese Diabetic Mice

Lin Yang | Jinzhe Ju | ... | Yongfu Wang
  • Special Issue
  • - Volume 2013
  • - Article ID 475960
  • - Research Article

B Epitope Multiplicity and B/T Epitope Orientation Influence Immunogenicity of Foot-and-Mouth Disease Peptide Vaccines

Esther Blanco | Carolina Cubillos | ... | Francisco Sobrino
  • Special Issue
  • - Volume 2013
  • - Article ID 601943
  • - Research Article

Selection of Conserved Epitopes from Hepatitis C Virus for Pan-Populational Stimulation of T-Cell Responses

Magdalena Molero-Abraham | Esther M. Lafuente | ... | Pedro A. Reche
  • Special Issue
  • - Volume 2013
  • - Article ID 262967
  • - Clinical Study

Potential Survival Benefit of Anti-Apoptosis Protein: Survivin-Derived Peptide Vaccine with and without Interferon Alpha Therapy for Patients with Advanced or Recurrent Urothelial Cancer—Results from Phase I Clinical Trials

Toshiaki Tanaka | Hiroshi Kitamura | ... | Naoya Masumori
  • Special Issue
  • - Volume 2013
  • - Article ID 385615
  • - Research Article

Allergenic Characterization of New Mutant Forms of Pru p 3 as New Immunotherapy Vaccines

C. Gómez-Casado | M. Garrido-Arandia | ... | L. Tordesillas
Journal of Immunology Research
 Journal metrics
Acceptance rate40%
Submission to final decision91 days
Acceptance to publication32 days
CiteScore3.330
Impact Factor3.404
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.